IL6 and Behcet disease: IFX has been reported to exert its effects in BD via a number of mechanisms, including neutralization of TNF-α and subsequent suppression of γδT cell expansion, activation, and cytotoxic activity[20] and a decrease in the levels of CSF IL-6 through cytotoxic effects on monocytes/macrophages.[15] Further, IFX has been found to be effective in treating intestinal BD,[10–12,17] NBD,[13–15,17] and VBD.[16,17] However, most of these reports were case studies and retrospective cohort clinical studies, and little data are available from prospective clinical studies.